Immunogenicity and Safety Study of Half and Full Dose of Heterologous and Homologous COVID-19 Vaccine Booster in Adult Subjects in Indonesia (Bcov 21)
Outcome
To evaluate the antibody titres before and one month (+7 days) after booster dose with full and half booster dose of ChAdOx1;S, Comirnaty®, or CoronaVac®
Sponsor
Badan Penelitian dan Pengembangan Kesehatan
Date
-
Subjects
715 (329 primary astrazeneca + 386 primary Sinovac) subjects